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Polycomb regulation is coupled to cell cycle transition 
in pluripotent stem cells
Helena G. Asenjo1,2,3, Amador Gallardo1,2,3, Lourdes López-Onieva1,4, Irene Tejada1,2,3, 
Jordi Martorell-Marugán1,5, Pedro Carmona-Sáez1, David Landeira1,2,3*
When self-renewing pluripotent cells receive a differentiation signal, ongoing cell duplication needs to be coordi-
nated with entry into a differentiation program. Accordingly, transcriptional activation of lineage specifier genes and 
cell differentiation is confined to the G1 phase of the cell cycle by unknown mechanisms. We found that Polycomb 
repressive complex 2 (PRC2) subunits are differentially recruited to lineage specifier gene promoters across cell cycle in 
mouse embryonic stem cells (mESCs). Jarid2 and the catalytic subunit Ezh2 are markedly accumulated at target 
promoters during S and G2 phases, while the transcriptionally activating subunits EPOP and EloB are enriched 
during G1 phase. Fluctuations in the recruitment of PRC2 subunits promote changes in RNA synthesis and RNA 
polymerase II binding that are compromised in Jarid2 −/− mESCs. Overall, we show that differential recruitment of 
PRC2 subunits across cell cycle enables the establishment of a chromatin state that facilitates the induction of cell 
differentiation in G1 phase.
INTRODUCTION
Deciphering the molecular mechanisms regulating pluripotent stem 
cell differentiation is of fundamental importance to understand 
mammalian development and for safe application of pluripotent 
stem cell–based therapies (1). Self-renewing mouse embryonic stem 
cells (mESCs) can be derived from the developing mouse blastocyst 
and provide a well-established system to study the molecular basis 
of pluripotency and early development. mESCs can differentiate 
into all cell types of the adult organism. However, the ability of in-
dividual mESCs within the population to respond to differentiation 
stimuli can be markedly different (2–4). This reveals a key aspect of 
the regulation of pluripotent cell differentiation and poses an im-
portant handicap for the application of stem cell–based therapies to 
humans. The features determining the responsiveness of individual 
cells to differentiation cues are mostly unknown and are currently a 
subject of intense debate. Accumulated evidence indicates that tran-
scriptional activation of lineage specifier genes and cell differentiation 
in pluripotent cells is confined to the G1 phase of the cell cycle (5–8). 
This observation partly explains the observed functional heterogeneity 
of pluripotent cell populations and highlights a very important regu-
latory feature of stem cell differentiation. Despite its obvious relevance, 
very little is known about the molecular mechanisms underlying this 
type of regulation (9).
Polycomb group (PcG) proteins are a hallmark of epigenetic 
control in eukaryotes and key regulators of mammalian development, 
cancer progression, and stem cell differentiation (10, 11). In mESCs, 
PcG proteins associate to form Polycomb repressive complexes 1 
and 2 (PRC1 and PRC2) that catalyze H2AK119 monoubiquitination 
and H3K27 methylation, respectively (11). PRCs bind and repress 
hundreds of developmental regulator genes that will be activated 
later during cell differentiation (12, 13). In mESCs, PRC target re-
pressed genes display nucleosomes modified with functionally op-
posing histone modifications including H3K4me3 and H3K27me3 
(hence, the designation of bivalent chromatin), leaky production of 
transcripts, and binding of poised RNAPII (RNA polymerase II) 
phosphorylated on Ser5 (Ser5-RNAPII) (14–17). PRC2 is typically 
composed by core subunits Eed, Suz12, Rbbp4/7, and Ezh1/2 of which 
the last one harbors the histone methyltransferase catalytic function 
(11). PRC2 function is regulated by nonstoichiometric accessory 
subunits that are differentially expressed during development (11). 
mESCs express high levels of Jarid2 that recruits and enhances PRC2 
activity (11, 18–22). In addition, mESCs express the PRC2-interacting 
protein EPOP, which mediates recruitment of EloB and promote 
low-level transcription of bivalent genes (23). It has been proposed 
that Jarid2 and EPOP form mutually exclusive complexes (23). In 
agreement, studies of PcG proteins interactome have shown the exis-
tence of at least two types of PRC2 subcomplexes, one containing 
EPOP and PCL1-3 (Polycomb-like proteins 1 to 3) and another one 
containing Jarid2 and Aebp2 (11). They have been proposed to be 
termed PRC2.1 and PRC2.2, respectively (24). The functional rele-
vance of PRC2 subcomplexes specialization remains unknown.
In this study, we asked whether chromatin regulation by PRC2 
was linked to the preference of pluripotent cells to enter differenti-
ation in G1 phase. We found that recruitment of PRC2.1 complex to 
target promoters is favored in G1 phase, while binding of PRC2.2 
complex increases during S and G2-M phases, leading to gradual accu-
mulation of the catalytic subunit Ezh2 at bivalent promoters. This is 
accompanied by enhanced gene repression and accumulation of paused 
Ser5-RNAPII at bivalent promoters during S and G2-M phases. This cell 
cycle–dependent regulation is particularly evident at pioneering lineage 
specifiers, whose tight regulation is hindered in Jarid2 −/− mESCs. 
Together, our results strongly suggest that differential recruitment of 
PRC2 complexes across cell cycle is key to establish a chromatin state 
that facilitates the induction of cell differentiation in G1 phase.
RESULTS
Recruitment of Ezh2 to bivalent promoters increases during 
S and G2-M phases
We established wild-type mESCs that stably express the fluorescent 
ubiquitination-based cell cycle indicator (FUCCI) reporter system 
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(FUCCI-mESCs) (fig. S1A) (25)and used flow cytometry to isolate 
highly enriched populations of cells in G1 (83 ± 2%), S (55 ± 1%), 
and G2-M phases (81 ± 1%) (see Methods and table S1) (Fig. 1A). 
Genome-wide analysis of Ezh2 binding by chromatin immuno-
precipitation followed by sequencing (ChIP-seq) readily revealed the 
prevalence of recruitment of Ezh2 to chromatin in S and G2-M phases 
compared to G1 phase (Ezh2 binding peaks: 6316 in G1; 9630 in S; 
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Fig. 1. Recruitment of the PRC2 core subunit Ezh2 to bivalent genes increases during S and G2-M phases of the cell cycle. (A) Flow cytometry dot plot analysis of 
FUCCI-mESCs indicating sorting gates used to obtain cell populations enriched in G1 (Gate 1), S (Gate 2), and G2-M (Gate 3) cell cycle phases (left). Sorted cells were stained 
with propidium iodide and analyzed by flow cytometry (right). (B) Venn diagrams of bivalent genes previously published in (36–38). (C) Heatmaps of normalized Ezh2 
ChIP-seq reads around the TSS of HC bivalent promoters at different cell cycle phases. Heatmap of hypermethylated promoters is shown as a negative control. (D) Average 
binding profile of Ezh2 around the TSS of HC bivalent promoters in G1 (red), S (green), and G2-M (blue). (E) Quantification of Ezh2-binding signal at the promoter regions 
(−0.5 to +1.5 kb relative to TSS) of HC bivalent genes in indicated cell cycle phases. (F) Average binding profile of Ezh2 around the TSS of HC bivalent (black) and hyper-
methylated (gray) promoters in G1 phase. (G) Hierarchical clustering analysis of binding of Ezh2 to the promoter region (−0.5 to +1.5 kb relative to TSS) of HC bivalent genes 
at indicated phases of the cell cycle. Binding relative to the average is presented. (H) Genome browser view of Ezh2 ChIP-seq data across cell cycle at the Hoxd gene cluster. 
Suz12 binding was analyzed using published data (19). (I and J) Histogram showing enrichment of Ezh2 (I) or H3K27me3 (J) at PRC2 target promoter regions (Dach1, Sox7, 
Ascl1, Pax3, Msx1, and Nkx2-2) in G1 (black), S (gray), and G2-M (red) assayed by ChIP-qPCR. Active (Oct4, Nanog, and Hprt1) and hypermethylated (Myf5 and -5) gene 
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a list of high confidence Polycomb target bivalent genes [High con-
fidence (HC) bivalent, n = 1678] (Fig. 1B). As controls, we used 
transcriptionally active (n = 1557) and hypermethylated (n = 656) 
genes that are not targeted by PRC2 (see Methods and table S3). 
Heatmap analysis of Ezh2 binding to HC bivalent genes showed 
that recruitment of Ezh2 was increased as cells exit G1 and transit into 
S and G2-M phases (Fig. 1C). Comparison of Ezh2 binding at HC 
bivalent gene promoters showed that, although Ezh2 accumulates 
around the transcription start site (TSS) of bivalent genes at all cell 
cycle phases, the amount of Ezh2 bound gradually increases as cells exit 
G1 phase and transit through the cell cycle (Fig. 1, D and E, and fig. 
S1, B and C). Recruitment of Ezh2 in G1 phase appeared weak com-
pared to G2-M (Fig. 1, D and E), but it was evident when compared 
to hypermethylated promoters known to be devoid of PRC2 (Fig. 1F and 
fig. S1D). Analysis of Ezh2 binding at individual promoters revealed 
a very consistent and gradual accumulation of Ezh2 during S and 
G2-M phases in most (1576 of 1677; 93.9%) HC bivalent gene pro-
moters (see clusters I and II in Fig. 1G and fig. S1E) including the 
archetypical Hoxd gene cluster (Fig. 1H). These observations were 
confirmed by ChIP–quantitative polymerase chain reaction (qPCR) 
for Ezh2 and analysis of a subset of well-characterized (18) PRC2 tar-
get promoters (Fig. 1I). Increased binding of Ezh2 during S and 
G2-M phases was particularly obvious at bivalent promoters, but it 
could also be detected at bivalent gene bodies and other Ezh2-bound 
genomic regions (fig. S1F). Enhanced recruitment of Ezh2 upon G1 phase 
exit resulted in concomitant accumulation of H3K27me3 at bivalent 
promoters during S and G2-M phases (Fig. 1J). Thus, we concluded 
that binding of Ezh2 to target promoters is markedly enhanced 
upon G1 phase exit in mESCs.
Inverse binding patterns of Jarid2 and EPOP across cell cycle
We next asked whether accumulation of Ezh2 at bivalent promoters 
during S and G2-M phases reflected increased binding of PRC2.1, 
PRC2.2, or both. ChIP-seq analysis of Jarid2 binding in cell cycle–
sorted FUCCI-mESCs demonstrated that recruitment of Jarid2 to 
the promoter region of HC bivalent genes was augmented in S 
and G2-M phases compared to G1 phase (Fig. 2, A and B, and fig. S2, 
A and B). Increased recruitment of Jarid2 to target genes in S and 
G2-M phases was evident but quantitatively less accused than 
changes found in binding of Ezh2 across cell cycle (Fig. 1D). 
Notwithstanding, clustering analysis showed a very consistent 
tendency to accumulate Jarid2 in G2-M at individual HC bivalent genes 
(1404 of 1677; 83.7%) (see clusters I and II in Fig. 2C). Jarid2 was 
bound to most of the Ezh2-bound HC promoters in G2-M (1188 of 
1262; 94%) (fig. S2C), and binding of Jarid2 and Ezh2 around the TSS 
of HC bivalent gene promoters in G2-M displayed concordant dis-
tributions (Fig. 2D). Correlation analysis demonstrated that accu-
mulation of Jarid2 at target genes in S and G2-M phases correlates with 
increased recruitment of Ezh2 to the same promoter regions (Fig. 2E). 
Coordinated recruitment of Jarid2 and Ezh2 to target genes upon 
G1 phase exit was also observed at individual candidate regions (i.e., 
gene Adra2c) (Fig. 2F). While increased binding of Jarid2 to HC bivalent 
promoters was clear in G2-M compared to G1 phase (Fig. 2C), changes 
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Fig. 2. Binding of Jarid2 to target promoters increases during S and G2-M phases of the cell cycle. (A) Heatmaps of normalized ChIP-seq reads showing the binding 
of Jarid2 around the TSS of HC bivalent promoters at different cell cycle phases. Heatmap of hypermethylated promoters is shown as a negative control. (B) Average 
binding profile of Jarid2 around the TSS of HC bivalent promoters in G1 (red), S (green), and G2-M (blue). (C) Hierarchical clustering analysis of binding of Jarid2 to the 
promoter region (−0.5 to +1.5 kb relative to TSS) of HC bivalent genes at indicated phases of the cell cycle. Binding relative to the average is presented. (D) Heatmaps 
comparing the binding of Jarid2 and Ezh2 around the TSS of HC bivalent promoters in G2-M. (E) Linear regression analysis showing the correlation between the binding 
signals of Jarid2 and Ezh2 at HC bivalent promoters (−0.5 to +1.5 kb relative to TSS) at indicated cell cycle phases. (F) Genome browser view of Ezh2 and Jarid2 binding 
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the HC bivalent genes (cluster I, 899 genes; 64%) showed increased 
binding of Jarid2 in S phase compared to G1 phase; however, a smaller 
proportion of genes (cluster II, 505 genes; 36%) showed reduced 
binding of Jarid2 in this cell cycle phase (Fig. 2C). This pattern is in 
contrast with the homogeneous increase of Ezh2 binding at HC 
bivalent promoters in S phase (Fig. 1G) and suggests that recruit-
ment of Ezh2 to target genes in S phase might be Jarid2 indepen-
dent for this subset of bivalent genes (cluster II).
We next analyzed binding of the PRC2.1 subunit EPOP. In stark 
contrast to the binding pattern observed for Ezh2 and Jarid2, binding 
of EPOP around the TSS of HC bivalent genes was reduced in cells 
in G2-M (Fig. 3, A to C, and fig. S3, A and B). Clustering analysis 
showed that increased binding of EPOP in G1 phase compared to G2-M 
can be observed in most (1426 of 1677; 85%) bivalent gene promoters 
(see cluster I in fig. S3C). Increased recruitment of EPOP to target 
promoters in G1 phase was also observed by ChIP-qPCR for a repre-
sentative set of PRC2 target promoters (Fig. 3D). We next addressed 
whether increased binding of EPOP in G1 phase led to augmented 
recruitment of EloB in this cell cycle phase. As expected, ChIP-seq 
analysis showed that EloB is recruited to HC bivalent genes more pro-
foundly in G1 phase compared to S and G2-M phases in average (Fig. 3, 
E to G, and fig. S3, D and E) and individual gene (fig. S3F) analyses. 
Global levels of Ezh2, Jarid2, and EPOP across cell cycle were unchanged, 
indicating that differential recruitment to target genes is regulated 
by changes in protein interactions rather than changes in protein 
abundance (Fig. 3H and fig. S3, G and H). Together, these results 
demonstrate that Jarid2 and Ezh2 recruitment is increased during 
S and G2-M phases, while EPOP and EloB are preferentially bound 
to chromatin in G1 phase. This indicates that PRC2.1 complex is 
preferentially recruited to target promoters during G1 phase while 
PRC2.2 complex is favored during S and G2-M phases.
RNA synthesis is reduced and Ser5-RNAPII is accumulated at 
PRC2 target genes during S and G2-M phase
We next questioned whether changes in recruitment of PRC2 
subunits across cell cycle had functional consequences in the 
transcriptional regulation of target genes. To analyze low-level 
RNA transcription typically found at bivalent promoters, we 
used 4-thiouridine (4sU) tagging followed by high-throughput 
sequencing (4sU-seq). 4sU-seq permits the analysis of newly tran-
scribed RNA (fig. S4A) (26, 27) and thus allowed us to minimize 
contamination of RNA molecules produced in preceding phases 
of the cell cycle. We found increased production of RNA in G1 phase 
compared to S-G2-M at HC bivalent genes but not at promoters 
of active genes (Fig. 4, A and B, and fig. S4, B and C). Of 1655 HC 
bivalent genes, 974 genes showed differences in RNA production 
between G1 and G2-M. Among these, most of them (715; 73.4%) were 
down-regulated in G2-M compared to G1 phase (fig. S4D), reveal-
ing a consistent tendency of bivalent genes to be more strictly re-
pressed during S and G2-M phases than in G1 phase. In agreement, 
analysis of individual candidate genes confirmed that bivalent 
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Fig. 3. Binding of EPOP and EloB to bivalent promoters is enhanced in G1 phase. (A) Heatmaps showing the binding of EPOP around the TSS of HC bivalent promoters 
in G1 and G2-M. Heatmap of hypermethylated promoters is shown as a negative control. (B) Average binding profile of EPOP around the TSS of HC bivalent promoters 
in G1 (red) and G2-M (blue). (C) Boxplot of EPOP-binding signal at the promoter regions (−0.5 to +1.5 kb relative to TSS) of HC bivalent genes in indicated cell cycle phases. 
(D) Histogram showing enrichment of EPOP to PRC2 target promoter regions (Dach1, Sox7, Ascl1, Pax3, Msx1, and Nkx2-2) in G1 (black), S (gray), and G2-M (red) assayed by 
ChIP-qPCR. Active (Oct4, Nanog, and Hprt1) and hypermethylated (Myf5 and -5) gene promoters were used as negative controls. Means ± SEM of three experiments is 
shown. (E) Heatmaps showing the binding of EloB around the TSS of HC bivalent promoters in G1, S, and G2-M. Heatmap of hypermethylated promoters is shown as a 
negative control. (F) Average binding profile of EloB around the TSS of HC bivalent promoters in G1 (red), S (green), and G2-M (blue). (G) Quantification of EloB-binding 
signal at the promoter regions (−0.5 to +1.5 kb relative to TSS) of HC bivalent genes in indicated cell cycle phases. (H) Whole-cell lysate Western blots comparing Ezh2, 
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Fig. 4. RNA synthesis is down-regulated and Ser5-RNAPII is accumulated at PRC2 target promoters during S and G2-M phase. (A) Average RNA production from HC bivalent 
(left) and active (right) promoters in G1 (red), S (green), and G2-M (blue). (B) Boxplot comparing 4sU-seq reads mapped to the proximal promoter region (TSS to +3Kb) of 
HC bivalent genes in indicated cell cycle phases. (C) Genome browser view of RNA synthesis at indicated cell cycle phases at the bivalent gene Nes. Ezh2 binding was 
analyzed using published data (46). (D) Heatmaps showing the binding of Ser5-RNAPII around the TSS of HC bivalent promoters in G1, S, and G2-M. Heatmap of hyper-
methylated promoters is shown as a negative control. (E) Average binding profile of Ser5-RNAPII around the TSS of HC bivalent gene promoters in G1 (red), S (green), and 
G2-M (blue). (F) Quantification of Ser5-RNAPII–binding signal at the promoter regions (−0.5 to +1.5 kb relative to TSS) of HC bivalent genes in indicated cell cycle phases. 
(G) Hierarchical clustering analysis of binding of Ser5-RNAPII to the promoter region (−0.5 to +1.5 kb relative to TSS) of HC bivalent genes at indicated phases of the cell 
cycle. Binding relative to the average is presented. (H) Genome browser view of the binding of Ser5-RNAPII across cell cycle at the Hoxd gene cluster. Ezh2 binding was 
analyzed using published data (46). (I) Analysis by ChIP-qPCR of Ser5-RNAPII binding at PRC2 target promoter regions (Dach1, Sox7, Ascl1, Pax3, Msx1, and Nkx2-2) in G1 
(black), S (gray), and G2-M (red) assayed by ChIP-qPCR. Active (Oct4 and Nanog) and hypermethylated (Myf5 and -5) gene promoters were used as controls. Means ± SEM 
of three experiments is shown. (J) Venn diagram showing the overlap between HC bivalent genes overtly repressed in G2-M (FC > 1.5) and genes displaying accumulation 
of Ser5-RNAPII at their promoter region in G2-M (cluster I in Fig. 3G). (K) Linear regression analysis of the binding signals of Ezh2 and Ser5-RNAPII at HC bivalent promoters 
(−0.5 to +1.5 kb relative to TSS) at indicated cell cycle phases. (L) Histogram displaying the percentage of genes showing changes (G1 > G2-M or G1 < G2-M) of binding for 
Ezh2 (FC > 2), Jarid2 (FC > 1.3), Ser5-RNAPII (FC > 2), EPOP (FC > 1.5), EloB (FC > 1.5), and RNA production (FC > 1.5) during cell cycle transition. Genes that showed no 
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(Fig. 4C). The level of RNA synthesized from bivalent promoters 
in G1 phase was still very low compared to the level of RNA produced 
at active promoters (compare scale of y axis in HC bivalent and Active 
plots; Fig. 4A), indicating that transient alleviation of PRC2 repres-
sion in G1 results in increased leaky transcription rather than full 
activation of bivalent genes.
To address whether recruitment of Jarid2-Ezh2 and firmer repres-
sion of bivalent genes during S-G2-M were associated with changes 
in the activity of RNAPII, we analyzed binding of Ser5-RNAPII, 
typically associated with transcriptionally pausing and gene poising 
of bivalent genes in mESCs (28). We found augmented accumula-
tion of Ser5-RNAPII around the TSS of HC bivalent genes in S and 
G2-M phases as compared to G1 phase (Fig. 4, D to F, and fig. S4, E 
and F). Increased binding of Ser5-RNAPII was evident for most bivalent 
promoters (1324 of 1677; 78.9%) genes (see cluster I in Fig. 4G) and 
at individual candidate bivalent genomic domains (i.e., Hoxd gene 
cluster) (Fig. 4H). ChIP-qPCR analysis of a subset of PRC2 target 
genes further confirmed gradual accumulation of Ser5-RNAPII 
during S and G2-M phases compared to G1 phase (Fig. 4I). Most of 
HC bivalent genes (592 of 715; 82.7%) that showed reduced RNA 
synthesis in G2-M displayed accumulation of Ser5-RNAPII at their 
promoter region (Fig. 4J), suggesting that reduced production of RNA 
is coupled to RNAPII pausing at the promoters of bivalent genes 
during S and G2-M phases. Increased recruitment of Ezh2 (or Jarid2) 
during S and G2-M phases correlated with accumulation of Ser5-
RNAPII at target promoters at all phases of the cell cycle, and it 
became more evident during S and G2-M phases (Fig. 4K and fig. 
S4G). Together (Fig. 4L and fig. S4H), these observations indicate 
that increased recruitment of Jarid2-Ezh2 to target genes is associated 
with reduced binding of EPOP and EloB, pausing of transcription 
by RNAPII, and reduced production of leaky RNA during S and 
G2-M phases.
Cell cycle–dependent regulation of PRC2 is more evident at 
the promoter of developmental transcription factors
We reasoned that, because cell cycle–dependent regulation of bi-
valent genes involved changes in recruitment of Jarid2, Ezh2, EPOP, 
EloB, and Ser5-RNAPII, bivalent genes that are common targets of 
these proteins in asynchronous mESCs might display more accused 
regulation across cell cycle. Notably, we found that a set of 390 bi-
valent genes cobound by these factors (common target genes) (Fig. 5A) 
is very significantly enriched for transcription factors and DNA 
binding proteins (162 of 390 genes; P = 7.6 × 10−94), in contrast 
to the remaining 991 genes that are enriched for protein binding 
and transmembrane transporters (Fig. 5B). Common target genes 
included key pioneering factors involved in mesoderm, ectoderm, 
and endoderm differentiation (fig. S5A), suggesting that cell cycle–
dependent regulation of Polycomb recruitment modulates differen-
tiation to the three germ layers. In fitting, bivalent genes that 
showed more accused cell cycle–dependent changes in PRC2 bind-
ing were also enriched in a similar subset of transcription factors 
(fig. S5, B to E). Comparative analysis of PRC2 binding revealed 
that common targets are more profoundly bound by PRC2 sub-
units (Ezh2, Jarid2, and EPOP) and Ser5-RNAPII than remaining 
genes and that their differential recruitment of PRC2 subunits, 
Ser5-RNAPII, and RNA production across cell cycle are more accused 
(Fig. 5C and fig. S6, A and B). In agreement, analysis using pub-
lished data of PRC2 binding in asynchronous populations of mESCs 
showed that recruitment of Ezh2, Jarid2, EPOP, and EloB, as well as 
Eed, Suz12, Mtf2, and H3K27me3 was higher at the promoters of 
common targets than at the promoters of remaining genes (fig. S6C). 
In contrast, common targets were not enriched for trithorax protein 
MLL2 and H3K4me3 (fig. S6C). Together, these results indicate that 
the promoter regions of transcription factors that regulate cell differ-
entiation recruit higher levels of PRC2 subunits that are prominently 
regulated across cell cycle.
Cell cycle–dependent regulation of PRC2 is hindered 
in Jarid2 −/− mESCs
We next tested how the lack of the PRC2-recruiter Jarid2 affected 
the cell cycle–dependent regulation of PRC2. We derived FUCCI- 
Jarid2 −/− by introducing the FUCCI reporter system into previously 
derived Jarid2 −/− mESCs (fig. S7A) (20). Jarid2-depleted mESCs 
have been reported to display reduced binding of core PRC2 sub-
units and Ser5-RNAPII (18, 20) to bivalent promoters, but they show 
unchanged levels of EPOP binding at target genes (23). In fitting, 
depletion of Jarid2 hinders accumulation of H3K27me3 at target 
promoters during S and G2-M phases (Fig. 6A and fig. S7, B and C) 
where binding of Ezh2 and H3K27me3 is more accused in wild-type 
cells (Fig. 1). Analysis of RNA expression and binding of Ser5-
RNAPII revealed that depletion of Jarid2 and concomitant de-
crease in H3K27me3 at bivalent promoters results in derepression 
of RNA synthesis and loss of Ser5-RNAPII during S and G2-M phases 
(Fig. 6, B and C, and fig. S7, D and E). Analysis by ChIP-qPCR further 
confirmed that accumulation of paused Ser5-RNAPII at bivalent 
genes in S and G2-M phases is visibly reduced in Jarid2 −/− com-
pared to parental mESCs (Fig. 6D and fig. S7, F and G). Deple-
tion of Jarid2 had no detectable effect on the level of H3K27me3, 
Ser5-RNAPII binding, or RNA synthesis in cells in G1 phase (Fig. 6B 
and fig. S7B), suggesting that the function of Jarid2 and PRC2.2. might 
be specific of S and G2-M phases and dispensable in G1 phase. Overall, 
these results demonstrate that increased recruitment of Jarid2 and 
Ezh2 to bivalent genes during S and G2-M phases results in enhanced 
H3K27me3 deposition, pausing of RNAPII, and reduced production 
of RNA transcripts.
DISCUSSION
Our results show that recruitment of PRC2 complexes to target pro-
moters is regulated across cell cycle and indicate that PRC2.1 com-
plexes are preferentially recruited in G1 phase, while binding of PRC2.2 
is favored in S and G2-M phases (Fig. 6E). This is supported by our 
ChIP-seq analysis revealing augmented binding of EPOP and EloB 
(part of PRC2.1) to target promoters in G1 phase as opposed to increased 
binding of Jarid2 (part of PRC2.2) during S and G2-M phases. We 
found that binding of the catalytic subunit Ezh2 is markedly increased 
in S and G2-M phases compared to G1 phase, indicating that regula-
tion across cell cycle is not exclusive of accessory subunits but is 
also happening for the core catalytic subunit of the complex. This is 
in fitting with previous reports, suggesting a cell cycle–dependent 
regulation of Ezh2 binding by CDK1 and CDK2 phosphorylation 
(29). Jarid2 activity is known to favor high levels of PRC2 binding 
(18–22), while EPOP activity promotes the opposite (23). Thus, 
reduced recruitment of Ezh2 in G1 phase is probably a consequence 
of the accumulation of EPOP-PRC2 (PRC2.1) at the expense of Jarid2- 
PRC2 (PRC2.2) complexes in this cell cycle phase. We showed that 
nascent RNA produced in G1 phase is still in the range of leaky tran-
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although the amount of Ezh2 bound to promoters of bivalent genes 
in G1 phase is lower than in S and G2-M phases, it is probably enough 
to maintain substantial gene repression of target genes. Notwithstanding, 
repression of Ezh2 target genes in G1 phase might also be dependent 
on Ezh2-independent mechanisms (11), including the activity of Ezh1 
or PRC1 complexes.
We found that recruitment of Jarid2-PRC2 (PRC2.2) during S 
and G2-M phases leads to more robust gene repression of target 
bivalent genes; reduced production of RNA coupled with increased 
binding of paused Ser5-RNAPII in S and G2-M phases that is lost 
upon Jarid2 depletion. These observations, together with the known 
role of EPOP in recruiting EloB and promoting leaky transcription 
at bivalent genes (23, 30), support that recruitment of EPOP-PRC2 
(PRC2.1) to bivalent promoters in G1 phase favors a transcriptional 
permissive chromatin setup. Accumulation of Ser5-RNAPII is temporally 
coincident with recruitment of PRC2.2 during S and G2-M phases. 
Because simultaneous binding of PRCs and Ser5-RNAPII at bivalent 
gene promoters is a key defining feature of transcriptional priming, 
our results highlight a previously unanticipated regulation of gene 
priming within the pluripotent cell cycle. In particular, our results 
demonstrate that gene priming is evident during S and G2-M phases 
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Fig. 5. Cell cycle–dependent regulation of PRC2 is more accused at the promoter of developmental transcription factors. (A) Venn diagram showing overlap 
between HC bivalent genes that are targets of Ser5-RNAPII, Ezh2, Jarid2, EPOP, and EloB in asynchronous populations using published (23, 36) and our (Jarid2) datasets. 
(B) Gene Ontology (GO) analysis of common target and remaining genes. Bars represent the number of genes that fall into indicated GO categories. P value is shown next 
to each category. (C) Average binding profile of Ezh2, Jarid2, EPOP, Ser5-RNAPII, and RNA synthesis around the TSS of HC bivalent genes in G1 (red), S (green), and G2-M 
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G1 phase (low level of Ezh2 and Ser5-RNAPII), rather than being 
maintained until the exit of the pluripotent cell cycle.
Asynchronous populations of pluripotent cells display heter o genous 
expression of genes and cell differentiation ability (2–4). This is 
partly because G1 phase cells display elevated expression of develop-
mental regulators (8), and they are more prone to activate lineage- 
specific genes in response to differentiation cues (5, 6). We found that 
mESCs in G1 phase display a proactivation chromatin setup charac-
terized by enhanced binding of the PRC2 activating subunits EPOP 
and EloB, together with reduced binding of Jarid2 and Ezh2. We 
showed that this leads to alleviation of transcriptional repression in 
G1 phase. In fitting, it has been reported that human ESCs display 
increased H3K4me3 at the promoter of bivalent genes during G1 phase 
as compared to S and G2-M phases (31). Thus, given that derepres-
sion of PRC2 target genes is a critical early event during cell differ-
entiation (32), transient alleviation of Polycomb repression in G1 phase 
is a key observation to explain why pluripotent cells in G1 phase are 
more sensitive to differentiation signals.
Overall, in this study, we showed that Polycomb complexes subunit 
configuration is controlled by cell cycle–dependent mechanisms in 
mESCs and support that this type of regulation will be functionally 
relevant in the context of pluripotent cell differentiation. Our ob-
servations are in fitting with the established role of Polycomb as a 
regulator of pluripotent cell differentiation; however, to fully establish 
the relevance of cell cycle–mediated regulation of Polycomb func-
tion, future studies will need to address how the lack of Polycomb 
proteins at particular cell cycle phases affect cell differentiation. Be-
cause the general principles underlying Polycomb function are widely 
conserved from flies to humans (11), our discovery will probably be 
relevant for other model systems in which the regulation of gene 
expression by Polycomb needs to be coordinated with DNA replication 
and cell division, including adult stem cells and tumor cells (33). In addition, 
PRCs can also regulate gene activity in somatic G1 phase–arrested cells 
(33) and thus, in the future, it will be interesting to see to what extent 
differences in the regulation by Polycomb proteins in different model 














































Distance from TSS (kb)
−4.0 −2.0 0 2.0 4.0
Distance from TSS (kb)
−4.0 −2.0 0 2.0 4.0
G1 phase G2-M phase














































P = 10−4 


























































































































Fig. 6. Jarid2 −/− mESCs display altered cell cycle–dependent regulation of bivalent genes. (A) Analysis by ChIP-qPCR comparing the enrichment of H3K27me3 at 
PRC2 target promoter regions (Dach1, Sox7, Ascl1, Pax3, Msx1, and Nkx2-2) in Jarid2 fl/fl (black bars) and Jarid2 −/− (gray bars) in G2-M phase. Active (Oct4 and Nanog) gene 
promoters were used as negative controls. Means ± SEM of four experiments is shown. (B) Average RNA synthesis (top) and binding of Ser5-RNAPII (bottom) around the 
TSS of common target bivalent genes in G1 (left) and G2-M (right) in Jarid2 fl/fl (black lines) and Jarid2 −/− (gray lines) mESCs. (C) Quantification of RNA synthesis (top) and 
Ser5-RNAPII binding (bottom) in Jarid2 fl/fl and Jarid2 −/− cells in G1 and G2-M at common target genes. (D) Analysis by ChIP-qPCR comparing the binding of Ser5-RNAPII 
to PRC2 target promoter regions (Dach1, Sox7, Ascl1, Pax3, Msx1, and Nkx2-2) in Jarid2 fl/fl (black bars) and Jarid2 −/− (gray bars) in G2-M phase. Active (Oct4, Nanog, and 
Hprt) and hypermethylated (Myf5 and -5) gene promoters were used as controls. Means ± SEM of three experiments are shown. (E) Schematic diagram of observations 
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METHODS
ESCs growth, FUCCI, and flow cytometry
Stable FUCCI mES cell lines (background 129/Sv/C57BL/C6) were 
generated for parental and Jarid2 knockout mESCs (20) by transfect-
ing the ES-FUCCI plasmid (Addgene repository no. 62451) (34). mESCs 
expressing mCherry:hCdt and Citrine:Geminin were cultured in 5% 
CO2 at 37°C on 0.1% gelatin–coated dishes in Dulbecco’s modified 
Eagle’s medium knockout (Gibco) media supplemented with 10% 
fetal calf serum (FCS), leukemia-inhibiting factor (LIF), penicillin/
streptomycin (Gibco), l-glutamine (Gibco), 2-mercaptoethanol 
(Gibco), and hygromycin B (InvivoGen), as described previously (35). 
Upon trypsinization and resuspension in sorting buffer [phosphate- 
buffered saline (PBS), 2% FCS, 2 mM EDTA, and LIF] at 4°C, FUCCI- 
mESCs were cell sorted in an Aria Fusion flow cytometer equipped 
with 488- and 561-mm lasers to discriminate cells expressing 
citrine (516 nm/529 nm) and mCherry (587 nm/610 nm). Sorted 
cells were counted and 1 million cells were used typically for 
downstream genome-wide analysis. Purity and cell cycle profile 
of sorted cell populations were routinely checked by propidium 
iodide staining, followed by flow cytometry. While G1 and G2-M 
fractions were highly enriched for G1 and G2-M cells, respectively, 
S fraction was composed by less homogeneous cell populations; 
typically, 15% in G1, 55% in S, and 30% in G2-M (table S1).
Gene promoter classification
The list of bivalent genes (promoter positive for H3K4me3 and 
H3K27me3) (3753 genes) was described previously (36). HC bivalent 
gene list (1678 genes) was obtained by extracting bivalent genes con-
sistently described in three different studies (36–38). Active genes 
(1557 genes) were determined using published data (36): genes posi-
tive for H3K4me3, bound by phosphorylated (Ser5, Ser2, and Ser7), 
hypophosphorylated RNAPII (8WG16 antibody), with RNA expres-
sion higher than 20 Fragments Per Kilobase of transcript per Million 
mapped reads (FPKM) and negative for PRC2 binding (Ezh2, Suz12, 
and H3K27me3). Hypermethylated promoters in mESCs (more 
than 80% CpG methylation) were identified using published bisulfite 
sequencing data (39) and cross-analyzed with published data (36) to 
identify hypermethylated promoters transcriptionally silent (less than 
1 FPKM) and not bound by PRC2 (Ezh2, Suz12, and H3K27me3) 
(656 genes). See table S3 for complete gene lists.
ChIP-qPCR and sequencing
ChIP assays for H3K27me3, Ser5-RNAPII, Ezh2, Jarid2, and EPOP 
(table S4) were performed as described previously (36) with minor 
modifications: Typically, 1 million cell cycle–sorted cells were re-
suspended in 37°C complete media (200 l per million cells) and 
incubated in a rotating platform for 12 min with 1% formaldehyde 
at room temperature. To stop the reaction, glycine was added to 
a final concentration of 125 mM. Swelling and sonication buffers 
(protease and phosphatase inhibitors supplemented) were used at 
4°C in a proportion of 0.5 ml per million cells. Ezh2, H3K27me3, 
Jarid2, and EPOP ChIPs were carried without using bridge antibody. 
Chromatin and antibody were incubated in a rotating wheel at 4°C 
overnight. Protein G magnetic beads (Dynabeads, Invitrogen) were 
then added and incubated for 5 hours. Washes were carried out for 
5 min at 4°C with 1 ml of the following buffers: 1× sonication buffer, 
1× wash buffer A [50 mM Hepes (pH 7.9), 500 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, and 0.1% SDS], 1× 
wash buffer B [20 mM tris (pH 8.0), 1 mM EDTA, 250 mM LiCl, 
0.5% NP-40, and 0.5% Na-deoxycholate], and 2× TE buffer (pH 8). 
ChIP of EloB was performed as above but adding a chromatin double–
cross-link step as described in (23) with minor modifications: Cells 
were resuspended in PBS at 4°C after flow cytometry sorting and 
incubated with ChIP Cross-link Gold (Diagenode no. C01019027, 
0.8 l in 200 l of PBS per 1 million cells) in a rotating platform for 
30 min at room temperature. After one wash, step chromatin was 
cross-linked with 1% formaldehyde for 10 min at room temperature. 
ChIP-qPCR of Ezh2, H3K27me3, EPOP, and Ser5-RNAPII and 
quality control of all immunoprecipitated DNA samples were tested by 
qPCR using GoTaq qPCR Master Mix (Promega) with a QuantStudio 
6 Flex Real-time PCR System (Applied Biosystems). Enrichment was 
calculated relative to 1% input for all ChIPs except for Ser5-RNAPII 
that was normalized by loading the same amount of DNA as described 
previously (36). Details of antibodies and primers used are available 
in table S5.
Libraries of immunoprecipitated DNA in Ezh2, Jarid2, EPOP, 
and EloB ChIP-seqs were generated from 1 to 5 ng of starting 
DNA with the NEBNext Ultra DNA Library Prep kit for Illumina 
(no. 7370) according to the manufacturer’s instructions at Centre 
for Genomic Regulation (CRG) Genomics Core Facility (Barcelona) 
and sequenced using HiSeq 2500 Illumina technology. Library of 
Ser5-RNAPII ChIP-seq was performed using the NextFlex ChIP-Seq 
kit (Bioo Scientific no. NOVA-5143-01), starting with 4 ng of 
immunoprecipitated DNA and sequenced at Centre for Genomics 
and Oncological Research (GENYO, Granada) using Illumina tech-
nology (NextSeq 500) according to the manufacturer’s instructions. 
Twenty million to 30 million reads [50–base pair (bp) single reads] 
were obtained for each library.
Reads were aligned and quantified using STAR 2.5.2 (40) against 
GENCODE NCBI m37 (mm9) genome. SAMtools 1.3.1 (41) was 
used to discard alignments with a quality score <200 to remove multi-
mapping reads. Last, we used BamCompare from deepTools suite 
(42) to create bigwig files with the signal normalized by reads per 
million (RPM) and against an input sample. Peak calling was per-
formed with MACS2. Data mining of publicly available ChIP-seq 
datasets (Eed, Suz12, Ezh2, H3K27me3, Jarid2, EPOP, EloB, Mtf2, 
Mll2, and H3K4me3) were treated the same way. CoverageView 
(Coverage visualization package for R. R package version 1.20.0.) was 
used to calculate coverage around TSS.
Average normalized reads (RPM) for a genomic window of −0.5 
to +1.5 kb relative to TSS for each analyzed promoter was calculated 
and represented as boxplots and were subjected to clustering using 
Cluster 3.0, followed by the Java TreeViewer software. Log2 of bind-
ing values relative to the average were used. Average binding plots 
were generated by counting normalized reads every 10 bp. In 
heatmap analyses of reads density in ChIP-seq experiments, we 
log2-transformed RPMs and trimmed these values between the 
minimum 5th percentile and the maximum 95th percentile. To 
compare different samples, genes were ranked according to G2-M 
(Ezh2, Jarid2, and Ser5-RNAPII) or G1 phase (EPOP and EloB). 
Gene Ontology analysis was performed using the Gene Ontology 
knowledge database (geneontology.org).
4sU-tagging sequencing
4sU-seq experiments were carried out as described in (27) with 
minor modifications: Cells were treated with 4sU (500 M) during 
1 hour 37°C before trypsinization and flow cytometry sorting. 
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(Invitrogen). Isolated RNA was bioanalyzed (Agilent) and was sub-
jected to qPCR analysis as quality control. 4sU-RNA and total RNA 
samples were retrotranscribed using the RevertAid RT Reverse 
Transcription kit (Thermo Fisher Scientific no. K1691), treated with 
deoxyribonuclease I (Thermo Fisher Scientific 18068015) and were 
subjected to qPCR using primers designed to specifically amplify 
unspliced RNA (contiguous exon-intron sequences) and total RNA 
(exon sequences). Strand-specific 4sU-seq libraries were generated 
using 75 ng of 4sU-RNA and the NextFlex Rapid Directional RNA-seq 
kit (Bioo Scientific no. NOVA-5138-07) according to the manu-
facturer’s instructions. Libraries were quantified by NanoDrop 2000 
(Thermo Fisher Scientific) and bioanalyzed. Fifty million 75-bp 
paired-end reads per sample were sequenced using Illumina tech-
nology (NextSeq 500) at GENYO.
After quality control, we used SortMeRNA 2.1 software (43) to 
filter out ribosomal RNA reads. We aligned and quantified filtered 
reads with STAR 2.5.2 (40) using GENCODE NCBI m37 (mm9) as 
the reference genome. We used SAMtools 1.3.1 (41) to remove align-
ments with a quality score <200 to discard multimapping reads. Last, 
we used BamCompare from deepTools suite (42) to create bigwig 
files with normalized signal in RPM and with positive values for 
forward strand and negative values in reverse strand. To normalize 
gene expression values, we applied trimmed mean of M values (44) 
method with NOISeq package (45).
Western blot analysis and cell fractionation
Whole extracts were prepared for 1 million cells after flow cytometry 
sorting. Cells were pelleted and resuspended in 50 l of PBS and 
50 l of 2× Laemmli buffer [0.1 M tris (pH 6.8), 2% SDS, and 
5% glycerol] supplemented with protease and phosphatase inhibitors 
[1× EDTA-free inhibitor cocktail (Roche), 1 mM phenylmethyl-
sulfonyl fluoride, 5 mM NaF, and 2 mM Na3VO4]. Alternatively, 
1 million cell cycle–sorted FUCCI wild-type cells subjected to cell 
fractionation as previously described in (23). Equivalent amount of 
cells was loaded for Western blots. Western blotting was carried out 
using standard procedures. Quantification of band intensity and 
normalization with LaminB was carried out using ImageJ.
Statistical analysis
Statistical analyses were carried out using R 3.5.1. In boxplots, whiskers 
denote the interval within 1.5× the interquartile range, and P values 
were calculated using Mann-Whitney test (significant differences 
P < 0.0001). Average mapped reads around the TSS was carried out 
using analysis of variance (ANOVA), comparing all samples in a win-
dow of −0.5 to +1.5 kb from TSS (significant differences P < 0.0001). 
ChIP-qPCR statistical analysis was carried out for triplicates and using 
Student’s t test (significant differences P < 0.05).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/10/eaay4768/DC1
Fig. S1. Differential recruitment of the PRC2 catalytic subunit Ezh2 across cell cycle.
Fig. S2. Cell cycle–dependent regulation of Jarid2.
Fig. S3. Binding of EPOP and EloB to bivalent promoters is regulated across cell cycle.
Fig. S4. Transcriptional activity at PRC2 target genes is attenuated during S and G2-M phases.
Fig. S5. Cell cycle–regulated PRC2 targets are enriched in developmental transcription factors.
Fig. S6. PRC2 target promoters that are regulated across cell cycle display higher levels of PRC2 
binding.
Fig. S7. Jarid2 −/− mESCs display abnormal regulation of H3K27me3, Ser5-RNAPII, and RNA 
synthesis during S phase of the cell cycle.
Table S1. Purity check of cell cycle–sorted mESCs used in ChIP-seq experiments.
Table S2. Analysis of peaks detected in ChIP-seq experiments.
Table S3. List of genes used in this manuscript.
Table S4. ChIP-seq enrichment and 4sU-seq expression values of HC bivalent genes.
Table S5. Table listing reagents and published datasets used in this manuscript.
View/request a protocol for this paper from Bio-protocol.
REFERENCES AND NOTES
 1. M. Li, J. C. Izpisua Belmonte, Deconstructing the pluripotency gene regulatory network. 
Nat. Cell Biol. 20, 382–392 (2018).
 2. R. M. Kumar, P. Cahan, A. K. Shalek, R. Satija, A. Jay DaleyKeyser, H. Li, J. Zhang, K. Pardee, 
D. Gennert, J. J. Trombetta, T. C. Ferrante, A. Regev, G. Q. Daley, J. J. Collins, 
Deconstructing transcriptional heterogeneity in pluripotent stem cells. Nature 516, 
56–61 (2014).
 3. A. M. Klein, L. Mazutis, I. Akartuna, N. Tallapragada, A. Veres, V. Li, L. Peshkin, D. A. Weitz, 
M. W. Kirschner, Droplet barcoding for single-cell transcriptomics applied to embryonic 
stem cells. Cell 161, 1187–1201 (2015).
 4. T. S. Macfarlan, W. D. Gifford, S. Driscoll, K. Lettieri, H. M. Rowe, D. Bonanomi, A. Firth, 
O. Singer, D. Trono, S. L. Pfaff, Embryonic stem cell potency fluctuates with endogenous 
retrovirus activity. Nature 487, 57–63 (2012).
 5. S. Pauklin, L. Vallier, The cell-cycle state of stem cells determines cell fate propensity. Cell 
155, 135–147 (2013).
 6. D. Coronado, M. Godet, P.-Y. Bourillot, Y. Tapponnier, A. Bernat, M. Petit, M. Afanassieff, 
S. Markossian, A. Malashicheva, R. Iacone, K. Anastassiadis, P. Savatier, A short G1 phase is 
an intrinsic determinant of naïve embryonic stem cell pluripotency. Stem Cell Res. 10, 
118–131 (2013).
 7. Y. Sela, N. Molotski, S. Golan, J. Itskovitz-Eldor, Y. Soen, Human embryonic stem cells 
exhibit increased propensity to differentiate during the G1 phase prior 
to phosphorylation of retinoblastoma protein. Stem Cells 30, 1097–1108 (2012).
 8. A. M. Singh, J. Chappell, R. Trost, L. Lin, T. Wang, J. Tang, B. K. Matlock, K. P. Weller, H. Wu, 
S. Zhao, P. Jin, S. Dalton, Cell-cycle control of developmentally regulated transcription 
factors accounts for heterogeneity in human pluripotent cells. Stem Cell Reports 1, 
532–544 (2013).
 9. S. Dalton, Linking the cell cycle to cell fate decisions. Trends Cell Biol. 25, 592–600 
(2015).
 10. C. D. Allis, T. Jenuwein, The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 
487–500 (2016).
 11. B. Schuettengruber, H. M. Bourbon, L. Di Croce, G. Cavalli, Genome regulation by 
polycomb and trithorax: 70 years and counting. Cell 171, 34–57 (2017).
 12. T. I. Lee, R. G. Jenner, L. A. Boyer, M. G. Guenther, S. S. Levine, R. M. Kumar, B. Chevalier, 
S. E. Johnstone, M. F. Cole, K.-I. Isono, H. Koseki, T. Fuchikami, K. Abe, H. L. Murray, 
J. P. Zucker, B. Yuan, G. W. Bell, E. Herbolsheimer, N. M. Hannett, K. Sun, D. T. Odom, 
A. P. Otte, T. L. Volkert, D. P. Bartel, D. A. Melton, D. K. Gifford, R. Jaenisch, R. A. Young, 
Control of developmental regulators by polycomb in human embryonic stem cells. Cell 
125, 301–313 (2006).
 13. L. A. Boyer, K. Plath, J. Zeitlinger, T. Brambrink, L. A. Medeiros, T. I. Lee, S. S. Levine, 
M. Wernig, A. Tajonar, M. K. Ray, G. W. Bell, A. P. Otte, M. Vidal, D. K. Gifford, R. A. Young, 
R. Jaenisch, Polycomb complexes repress developmental regulators in murine embryonic 
stem cells. Nature 441, 349–353 (2006).
 14. J. K. Stock, S. Giadrossi, M. Casanova, E. Brookes, M. Vidal, H. Koseki, N. Brockdorff, 
A. G. Fisher, A. Pombo, Ring1-mediated ubiquitination of H2A restrains poised RNA 
polymerase II at bivalent genes in mouse ES cells. Nat. Cell Biol. 9, 1428–1435 (2007).
 15. M. G. Guenther, S. S. Levine, L. A. Boyer, R. Jaenisch, R. A. Young, A chromatin 
landmark and transcription initiation at most promoters in human cells. Cell 130, 
77–88 (2007).
 16. B. E. Bernstein, T. S. Mikkelsen, X. Xie, M. Kamal, D. J. Huebert, J. Cuff, B. Fry, A. Meissner, 
M. Wernig, K. Plath, R. Jaenisch, A. Wagschal, R. Feil, S. L. Schreiber, E. S. Lander, A bivalent 
chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 
315–326 (2006).
 17. V. Azuara, P. Perry, S. Sauer, M. Spivakov, H. F. Jørgensen, R. M. John, M. Gouti, 
M. Casanova, G. Warnes, M. Merkenschlager, A. G. Fisher, Chromatin signatures 
of pluripotent cell lines. Nat. Cell Biol. 8, 532–538 (2006).
 18. D. Landeira, S. Sauer, R. Poot, M. Dvorkina, L. Mazzarella, H. F. Jørgensen, C. F. Pereira, 
M. Leleu, F. M. Piccolo, M. Spivakov, E. Brookes, A. Pombo, C. Fisher, W. C. Skarnes, 
T. Snoek, K. Bezstarosti, J. Demmers, R. J. Klose, M. Casanova, L. Tavares, N. Brockdorff, 
M. Merkenschlager, A. G. Fisher, Jarid2 is a PRC2 component in embryonic stem cells 
required for multi-lineage differentiation and recruitment of PRC1 and RNA polymerase II 
to developmental regulators. Nat. Cell Biol. 12, 618–624 (2010).
 19. D. Pasini, P. A. C. Cloos, J. Walfridsson, L. Olsson, J.-P. Bukowski, J. V. Johansen, M. Bak, 
N. Tommerup, J. Rappsilber, K. Helin, JARID2 regulates binding of the polycomb 









Asenjo et al., Sci. Adv. 2020; 6 : eaay4768     4 March 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
11 of 11
 20. X. Shen, W. Kim, Y. Fujiwara, M. D. Simon, Y. Liu, M. R. Mysliwiec, G.-C. Yuan, Y. Lee, 
S. H. Orkin, Jumonji modulates polycomb activity and self-renewal versus differentiation 
of stem cells. Cell 139, 1303–1314 (2009).
 21. J. C. Peng, A. Valouev, T. Swigut, J. Zhang, Y. Zhao, A. Sidow, J. Wysocka, Jarid2/Jumonji 
coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent 
cells. Cell 139, 1290–1302 (2009).
 22. G. Li, R. Margueron, M. Ku, P. Chambon, B. E. Bernstein, D. Reinberg, Jarid2 and PRC2, 
partners in regulating gene expression. Genes Dev. 24, 368–380 (2010).
 23. M. Beringer, P. Pisano, V. di Carlo, E. Blanco, P. Chammas, P. Vizán, A. Gutiérrez, S. Aranda, 
B. Payer, M. Wierer, L. di Croce, EPOP functionally links elongin and polycomb 
in pluripotent stem cells. Mol. Cell 64, 645–658 (2016).
 24. S. Hauri, F. Comoglio, M. Seimiya, M. Gerstung, T. Glatter, K. Hansen, R. Aebersold, R. Paro, 
M. Gstaiger, C. Beisel, A high-density map for navigating the human polycomb 
complexome. Cell Rep. 17, 583–595 (2016).
 25. A. Sakaue-Sawano, H. Kurokawa, T. Morimura, A. Hanyu, H. Hama, H. Osawa, S. Kashiwagi, 
K. Fukami, T. Miyata, H. Miyoshi, T. Imamura, M. Ogawa, H. Masai, A. Miyawaki, Visualizing 
spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132, 487–498 (2008).
 26. L. Windhager, T. Bonfert, K. Burger, Z. Ruzsics, S. Krebs, S. Kaufmann, G. Malterer, 
A. L'Hernault, M. Schilhabel, S. Schreiber, P. Rosenstiel, R. Zimmer, D. Eick, C. C. Friedel, 
L. Dölken, Ultrashort and progressive 4sU-tagging reveals key characteristics of RNA 
processing at nucleotide resolution. Genome Res. 22, 2031–2042 (2012).
 27. A. J. Rutkowski, L. Dölken, High-resolution gene expression profiling of RNA synthesis, 
processing, and decay by metabolic labeling of newly transcribed RNA using 
4-thiouridine. Methods Mol. Biol. (Clifton, N.J.) 1507, 129–140 (2017).
 28. E. Brookes, A. Pombo, Modifications of RNA polymerase II are pivotal in regulating gene 
expression states. EMBO Rep. 10, 1213–1219 (2009).
 29. G. Caretti, D. Palacios, V. Sartorelli, P. L. Puri, Phosphoryl-EZH-ion. Cell Stem Cell 8, 
262–265 (2011).
 30. R. Liefke, V. Karwacki-Neisius, Y. Shi, EPOP interacts with elongin BC and USP7 
to modulate the chromatin landscape. Mol. Cell 64, 659–672 (2016).
 31. A. M. Singh, Y. Sun, L. Li, W. Zhang, T. Wu, S. Zhao, Z. Qin, S. Dalton, Cell-cycle control 
of bivalent epigenetic domains regulates the exit from pluripotency. Stem Cell Reports 5, 
323–336 (2015).
 32. L. Morey, A. Santanach, L. Di Croce, Pluripotency and epigenetic factors in mouse 
embryonic stem cell fate regulation. Mol. Cell. Biol. 35, 2716–2728 (2015).
 33. R. Margueron, D. Reinberg, The polycomb complex PRC2 and its mark in life. Nature 469, 
343–349 (2011).
 34. H. L. Sladitschek, P. A. Neveu, MXS-chaining: A highly efficient cloning platform 
for imaging and flow cytometry approaches in mammalian systems. PLOS ONE 10, 
e0124958 (2015).
 35. D. Landeira, H. Bagci, A. R. Malinowski, K. E. Brown, J. Soza-Ried, A. Feytout, Z. Webster, 
E. Ndjetehe, I. Cantone, H. G. Asenjo, N. Brockdorff, T. Carroll, M. Merkenschlager, A. G. Fisher, 
Jarid2 coordinates nanog expression and PCP/Wnt signaling required for efficient ESC 
differentiation and early embryo development. Cell Rep. 12, 573–586 (2015).
 36. E. Brookes, I. de Santiago, D. Hebenstreit, K. J. Morris, T. Carroll, S. Q. Xie, J. K. Stock, 
M. Heidemann, D. Eick, N. Nozaki, H. Kimura, J. Ragoussis, S. A. Teichmann, A. Pombo, 
Polycomb associates genome-wide with a specific RNA polymerase II variant, 
and regulates metabolic genes in ESCs. Cell Stem Cell 10, 157–170 (2012).
 37. T. S. Mikkelsen, M. Ku, D. B. Jaffe, B. Issac, E. Lieberman, G. Giannoukos, P. Alvarez, 
W. Brockman, T.-K. Kim, R. P. Koche, W. Lee, E. Mendenhall, A. O’Donovan, A. Presser, 
C. Russ, X. Xie, A. Meissner, M. Wernig, R. Jaenisch, C. Nusbaum, E. S. Lander, 
B. E. Bernstein, Genome-wide maps of chromatin state in pluripotent and lineage-
committed cells. Nature 448, 553–560 (2007).
 38. M. Ku, R. P. Koche, E. Rheinbay, E. M. Mendenhall, M. Endoh, T. S. Mikkelsen, A. Presser, 
C. Nusbaum, X. Xie, A. S. Chi, M. Adli, S. Kasif, L. M. Ptaszek, C. A. Cowan, E. S. Lander, 
H. Koseki, B. E. Bernstein, Genomewide analysis of PRC1 and PRC2 occupancy identifies 
two classes of bivalent domains. PLOS Genet. 4, e1000242 (2008).
 39. H. Kobayashi, T. Sakurai, M. Imai, N. Takahashi, A. Fukuda, O. Yayoi, S. Sato, 
K. Nakabayashi, K. Hata, Y. Sotomaru, Y. Suzuki, T. Kono, Contribution of intragenic DNA 
methylation in mouse gametic DNA methylomes to establish oocyte-specific heritable 
marks. PLOS Genet. 8, e1002440 (2012).
 40. A. Dobin, T. R. Gingeras, Mapping RNA-seq reads with STAR. Curr. Protoc. Bioinformatics 
51, 11.14.11–11.14.19 (2015).
 41. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, 
R. Durbin; 1000 Genome Project Data Processing Subgroup, The sequence alignment/
map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
 42. F. Ramírez, D. P. Ryan, B. Grüning, V. Bhardwaj, F. Kilpert, A. S. Richter, S. Heyne, F. Dündar, 
T. Manke, deepTools2: A next generation web server for deep-sequencing data analysis. 
Nucleic Acids Res. 44, W160–W165 (2016).
 43. E. Kopylova, H. Touzet, L. Noé, SortMeRNA: Fast and accurate filtering of ribosomal RNAs 
in metatranscriptomic data. Bioinformatics 28, 3211–3217 (2012).
 44. M. D. Robinson, A. Oshlack, A scaling normalization method for differential expression 
analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
 45. S. Tarazona, P. Furió-Tarí, D. Turrà, A. Di Pietro, M. J. Nueda, A. Ferrer, A. Conesa, Data 
quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. 
Nucleic Acids Res. 43, e140–e140 (2015).
 46. H. Marks, T. Kalkan, R. Menafra, S. Denissov, K. Jones, H. Hofemeister, J. Nichols, A. Kranz, 
A. Francis Stewart, A. Smith, H. G. Stunnenberg, The transcriptional and epigenomic 
foundations of ground state pluripotency. Cell 149, 590–604 (2012).
Acknowledgments: We are very grateful to A. Pombo, E. Brookes, and L. Dölken for sharing in 
house protocols and technical advice for Ser5-RNAPII and 4sU-seq analyses; to L. Di Croce for 
sharing EPOP and EloB homemade antibodies and providing scientific advice; and to core 
facilities in GENYO and in particular, to the flow cytometry and genomics units. We also thank 
the genomics unit at the CRG for assistance with ChIP-seq experiments. This study was 
supported by the Spanish Ministry of Economy and Competitiveness (SAF2013-40891-R and 
BFU2016-75233-P) and the Andalusian Regional Government (PC-0246-2017). D.L. is a Ramón 
y Cajal researcher of the Spanish Ministry of Economy and Competitiveness (RYC-2012-10019). 
Author contributions: D.L. designed the study. H.G.A. and D.L. wrote the manuscript. H.G.A., 
A.G., L.L.-O., and I.T. designed, performed, and analyzed experiments. J.M.-M. and P.C.-S. 
carried out bioinformatic analysis. Competing interests: The authors declare that they have 
no competing interests. Data and materials availability: All data needed to evaluate the 
conclusions in the paper are present in the paper and/or the Supplementary Materials. 
Datasets are available at GEO-NCBI with accession number GSE128851 (www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE128851). Additional data related to this paper may be 
requested from the authors.
Submitted 22 June 2019
Accepted 11 December 2019
Published 4 March 2020
10.1126/sciadv.aay4768
Citation: H. G. Asenjo, A. Gallardo, L. López-Onieva, I. Tejada, J. Martorell-Marugán, P. Carmona-Sáez, 
D. Landeira, Polycomb regulation is coupled to cell cycle transition in pluripotent stem cells. 









Polycomb regulation is coupled to cell cycle transition in pluripotent stem cells
David Landeira
Helena G. Asenjo, Amador Gallardo, Lourdes López-Onieva, Irene Tejada, Jordi Martorell-Marugán, Pedro Carmona-Sáez and
DOI: 10.1126/sciadv.aay4768






This article cites 46 articles, 4 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
 is a registered trademark of AAAS.Science AdvancesYork Avenue NW, Washington, DC 20005. The title 
(ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 NewScience Advances 
License 4.0 (CC BY-NC).
Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial 
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of
 on A
pril 2, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
